1666P Lower virus neutralizing titers against SARS-CoV-2 Omicron strain after third dose BNT162b2 following primo-vaccination with ChAdOx1 versus BNT162b2 in cancer patients

por Debie, Y., Van Audenaerde, J., Vandamme, T., Croes, L., Teuwen, L-A.M.N., Verbruggen, L., Vanhoutte, G., Marcq, E., Le Blon, D., Peeters, B., M.E. Goossens, Arien, K., Anguille, S., Smits, E., Vulsteke, C., Lion, E., Peeters, M., van Dam, P.A.
Publicado 2022

Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment

por Peeters, M., Verbruggen, L., Teuwen, L., Vanhoutte, G., Vande Kerckhove, S., Peeters, B., Raats, S., Van der Massen, I., De Keersmaecker, S., Debie, Y., Huizing, M., Pannus, P., Neven, K., Ariën, K.K., Martens, G.A., Van Den Bulcke, M., Roelant, E., Desombere, I., Anguille, S., Goossens, M., Vandamme, T., van Dam, P.
Publicado 2021